Equities

Mabwell Shanghai Bioscience Co Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Mabwell Shanghai Bioscience Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)37.07
  • Today's Change0.04 / 0.11%
  • Shares traded4.17m
  • 1 Year change+129.54%
  • Beta1.9992
Data delayed at least 15 minutes, as of Feb 11 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Mabwell Shanghai Bioscience Co Ltd is a China-based company mainly engaged in the research, development, production and sales of innovative drugs and biosimilars. The Company's main products are antibodies, antibody drug conjugates (ADCs) drugs, recombinant proteins, small molecule chemical drugs and other drugs. The Company focuses on oncology and age-related diseases, such as immunology, ophthalmology, orthopedics and other fields. The Company conducts business in both domestic and overseas markets.

  • Revenue in CNY (TTM)624.52m
  • Net income in CNY-947.49m
  • Incorporated2017
  • Employees1.36k
  • Location
    Mabwell Shanghai Bioscience Co Ltd4th Floor, Building 3No 576 (Chuangxiang Garden)Libing Rd, Pudong New AreaSHANGHAI 201210ChinaCHN
  • Phone+86 2 158332260
  • Fax+86 2 158585793
  • Websitehttps://www.mabwell.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Beijing Sun-Novo Pharma Research Co Ltd1.02bn133.01m7.73bn1.36k56.816.65--7.591.211.219.2310.380.474535.481.28653,956.406.0411.3910.4918.8248.6053.3112.7219.661.789.970.335511.2915.7035.80-3.9830.213.50--
Shanghai Medicilon Inc1.08bn-231.86m9.16bn2.27k--4.44--8.49-1.75-1.758.0415.360.37598.561.68459,338.00-8.083.66-9.994.6316.2731.15-21.496.672.19--0.150840.97-24.0118.22-896.21--2.54--
Bio-Thera Solutions Ltd845.32m-368.84m10.05bn1.17k--20.75--11.88-0.8908-0.89082.041.170.37020.77225.96---16.15-16.38-33.76-22.2274.9977.05-43.63-62.110.4617-34.120.573--5.44302.90-29.34--11.14--
HitGen Inc498.51m114.11m12.12bn483.00107.148.24--24.310.28240.28241.243.670.27266.374.691,032,114.006.183.066.873.3655.2353.5522.6714.485.126.590.167434.3214.9910.0826.13-15.653.16--
InventisBio Co Ltd180.53m-116.28m13.55bn185.00--8.14--75.06-0.2012-0.20120.31222.880.0988--1.03975,824.70-6.36-32.89-6.76-35.2299.41---64.41-682.73----0.0127---9.0225.0015.41---3.97--
Mabwell Shanghai Bioscience Co Ltd624.52m-947.49m14.80bn1.36k--19.44--23.69-2.37-2.371.561.900.13840.345814.57441,048.00-21.06-29.90-36.19-36.1888.7285.56-152.14-1,188.680.8093-10.820.7353--56.2846.680.9031--12.25--
Sinocelltech Group Ltd1.89bn-310.15m18.08bn2.28k------9.58-0.6964-0.69644.24-0.10830.54580.43253.04828,989.10-8.37-22.66-29.60-48.2593.5195.52-15.33-42.960.5008-0.67531.02--33.13294.24127.39--23.95--
BeBetter Med Inc-100.00bn-100.00bn19.60bn150.00--91.01----------0.4785----------------------------0.0116------67.59------
Data as of Feb 11 2026. Currency figures normalised to Mabwell Shanghai Bioscience Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

14.78%Per cent of shares held by top holders
HolderShares% Held
Penghua Fund Management Co., Ltd.as of 30 Jun 20255.86m2.91%
Aegon-Industrial Fund Management Co., Ltd.as of 30 Jun 20254.12m2.05%
ICBC UBS Asset Management Co. Ltd.as of 30 Jun 20253.59m1.78%
Truvalue Asset Management Co. Ltd.as of 30 Jun 20253.17m1.57%
China Universal Asset Management Co., Ltd.as of 30 Jun 20252.52m1.25%
Fullgoal Fund Management Co., Ltd.as of 30 Jun 20252.46m1.22%
China Southern Asset Management Co., Ltd.as of 30 Jun 20252.29m1.14%
China Asset Management Co., Ltd.as of 30 Jun 20252.02m1.00%
Ping An Fund Management Co., Ltd.as of 30 Jun 20251.99m0.99%
HSBC Jintrust Fund Management Co. Ltd.as of 30 Jun 20251.77m0.88%
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.